75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Condensed Balance Sheets (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) 2
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - Condensed Statements of Cash Flows (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Organization and Principal Activities
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Balance Sheet Components
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Capital Structure
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - License Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Loan and security agreements
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Related Party Transactions
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Net Loss Per Share
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Balance Sheet Components (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Capital Structure (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Loan and Security Agreements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Net loss per share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Organization and principal activities - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Summary of Significant Accounting Policies - Summary of Selected Financial Information with Respect to Operating Segment (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Marketable securities - Summary of Amortized Cost, Gross Unrealized Holding Gains and Losses, and Fair Value of the Company's Cash Equivalents Marketable Securities by Major Security Type (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Balance Sheet Components - Summary of Accrued Expenses and Other Current Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Capital Structure - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Capital Structure - Schedule of Common Stock Reserved for Future Issuance (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense - Summary of Components of Stock-based Compensation Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense - Summary of Components of Stock-based Compensation Expense (Details) [Default]
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - License Agreements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Commitments and Contingencies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Loan and Security Agreements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Loan and Security Agreements - Summary of Tranche 1A Loan (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Loan and Security Agreements - Summary of Tranche 1A Loan (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Loan and Security Agreements - Summary of Future Principal Loan Payments on Currently Outstanding Tranche 1A Loan (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Loan and Security Agreements - Summary of Future Principal Loan Payments on Currently Outstanding Tranche 1A Loan (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Income Taxes - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Net loss per share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Net loss per share - Summary of Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Subsequent events - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Line of Credit Facility [Line Items]
Debt Repaid On Or Within 24 Months Of Closing Date [Member]
Debt Repaid On Or Within 24 Months Of Closing Date.
Debt Repaid on or Within 24 Months Of Closing Date
Warrants price per share exercisable and will not expire
Warrants price per share exercisable and will not expire.
Maturities of marketable securities
Proceeds from Sale and Maturity of Marketable Securities
Convertible Preferred Stock, Shares Issued upon Conversion
Convertible preferred stock converted into common stock
Common Stock, Capital Shares Reserved for Future Issuance
Total
Common stock shares reserved
Neurocrine License Agreement
Neurocrine License Agreement [Member]
Neurocrine license agreement.
Schedule of Accrued Liabilities [Table Text Block]
Summary of Accrued Expenses and Other Current Liabilities
Preferred Stock, Shares Issued
Preferred stock, shares issued
Preferred stock issued
Weighted-average Shares of Common Stock Outstanding
Weighted-average shares of common stock outstanding.
Weighted-average shares of common stock outstanding
Proceeds from underwritten registered offering, net
Proceeds From Underwritten Registered Offering
Proceeds From Underwritten Registered Offering.
Long-Term Debt, Maturity, Year Three
2029
Commitments and Contingencies
Commitments and contingencies (Note 9)
Net Proceeds from Issuance of Common Stock and Pre-Funded Warrants Pursuant to Underwriting Agreement
Net proceeds from issuance of common stock and pre-funded warrants pursuant to underwriting agreement.
Net proceeds from issuance of common stock and pre-funded warrants pursuant to underwriting agreement
Weighted Average Number of Shares Outstanding, Diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted-average shares of common stock outstanding used in the calculation of net loss per share, diluted
Weighted-average shares of common stock outstanding used to compute net loss per share diluted :
Stock Repurchased During Period, Shares
Repurchase of early exercised stock options, Shares
Stock-based compensation expense
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
Interest Receivable, Current
Interest receivable
Minimum [Member]
Minimum
Sale Of Stock, Aggregate Commission Percentage
Sale Of Stock, Aggregate Commission Percentage
Commission for agent on sales
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total
Issuance of common stock upon vesting of restricted stock awards/Issuance of restricted stock, Shares
Long-Term Debt, Maturity, Year Two
2028
Private Placement [Member]
Private Placement
Preferred Stock, Shares Outstanding
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock, shares outstanding
Preferred stock outstanding
Fair Value, Recurring [Member]
Fair Value, Recurring
Maximum Benefically Owned Threshold Percentage Limit
Maximum benefically owned threshold percentage limit.
Maximum benefically owned threshold percentage limit
Common Stock, Shares, Issued
Common stock, shares issued
Common stock, shares, issued
Other Expenses
Offering expenses
Term loan facility
Debt Instrument, Face Amount
Income Tax Expense (Benefit)
Income Tax Expense (Benefit), Total
Income tax expense
Income tax benefit (expense)
Income tax provision (benefit)
Counterparty Name [Domain]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Unites, Issued and Outstanding
Restricted Stock Units
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Warrants to purchase common stock
Pre-funded warrants issued
Draw Down Fee For Each Subsequent Term Loan Percentage
Draw down fee for each subsequent term loan percentage.
Draw down fee for each subsequent term loan percentage
Conversion of redeemable convertible preferred stock to common stock upon initial public offering
Stock Issued During Period, Value, Conversion of Convertible Securities
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Subsequent Event Type [Domain]
Liabilities, Fair Value Adjustment
Change in fair value of convertible promissory notes
Change in fair value of convertible promissory notes
Change in fair value of the derivative
Add: weighted-average shares of common stock to be issued upon exercise of pre-funded warrants
Add:weighted-Averagesharesofcommonstocktobeissueduponexerciseofpre-fundedwarrants
Add:weighted-Average Shares of Common Stock to be Issued upon Exercise of Pre-funded warrants.
Period Additional Term Loan Tranches Available from Closing Date
Period additional term loan tranches available from closing date.
Period additional term loan tranches available from closing date
Convertible Notes
Convertible Notes [Member]
Convertible notes.
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum
Percentage of number of shares reserved for issuance
Market Capitalization
Market capitalization.
Market capitalization
General and administrative expenses
General and Administrative Expense
General and Administrative Expense, Total
General and administrative
Income Statement [Abstract]
Beneficially owned threshold percentage limit
Beneficially owned threshold percentage limit.
Shares Reserved under 2025 Equity Incentive Plan and 2019 Equity Incentive Plan
Shares Reserved Under Twenty Twenty Five Equity Incentive Plan And Twenty Nineteen Equity Incentive Plan [Member]
Shares reserved under 2025 Equity Incentive Plan and 2019 Equity Incentive Plan member.
Net loss per share, basic
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Net loss per share, basic:
Document Period End Date
Minimum cash and cash equivalents percentage of outstanding debt2.
Minimum Cash And Cash Equivalents Percentage Of Outstanding Debt2
Decrease in cash and cash equivalents of percentage of outstanding loan amount
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Property, Plant, and Equipment, Total
Purchases of property and equipment
Common Stock, Shares Authorized
Common stock, shares authorized
Authorized common stock shares
Additional Upfront Payment Receivable
Additional Upfront payment receivable.
Additional Upfront Payment Receivable
Statement of Stockholders' Equity [Abstract]
Series B Redeemable Convertible Preferred Stock [Member]
Series B Redeemable Convertible Preferred Stock
Series B Redeemable Convertible Preferred Stock.
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Upfront Payment Received
Upfront payment received.
Upfront Payment Received
Short-term Marketable Securities
Marketable Securities Current [Member]
Marketable securities, current.
Decrease in cash and cash equivalents of percentage of outstanding loan amount
Decrease in Cash And Cash Equivalents Percentage Of Outstanding Debt
Decrease in cash and cash equivalents percentage of outstanding debt.
Term loan facility, interest rate percentage
Debt Instrument, Interest Rate, Stated Percentage
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent
Percentage of purchase price of common stock
Assets
Total assets
Title of 12(b) Security
Aggregate milestone Payments Upon The Completion Of Certain Clinical And Regulatory Milestones
Milestone payment paid upon clinical and regulatory milestones
Milestone payment to be paid upon achivement of clinical and regulatory milestones
Milestone payment to be paid upon achivement of clinical and regulatory milestones.
Preferred Stock, Value, Issued
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Stock Issued During Period, Value, Stock Options Exercised
Exercise of stock options
Liabilities, Fair Value Disclosure [Abstract]
Liabilities
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized
Increased number of common stock shares reserved
Shares Reserved Under Twenty Nineteen Equity Incentive Plan And Twenty Twenty Five Equity Incentive Plan [Member]
Shares Reserved Under 2019 Equity Incentive Plan And 2025 Equity Incentive Plan.
Shares reserved under 2019 Equity Incentive Plan and 2025 Equity Incentive Plan
Restricted Cash Fair Value Disclosure
Restricted cash fair value disclosure.
Restricted cash
Payment of success fee derivative
Payment of success fee derivative.
Payment of success fee derivative
Payment of success fee derivative
Proceeds from Issuance of Long-Term Debt
Proceeds from Issuance of Long-Term Debt, Total
Line of Credit Facility, Interest Rate During Period
Line of credit facility, interest rate percentage
Interest rate
Cash and Cash Equivalents [Domain]
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Other comprehensive loss:
Segment Reporting [Table Text Block]
Summary of Selected Financial Information with Respect to Operating Segment
Interest and Other Income
Interest and other income, net
Segment other income, net
Increase (Decrease) in Operating Lease Liability
Operating lease liabilities
Equity, Attributable to Parent
Equity, Attributable to Parent, Ending Balance
Equity, Attributable to Parent, Beginning Balance
Total stockholders' equity
Initial term loan
Initial term loan
Initial term loan
Entity Address, Address Line Two
Other Assets, Noncurrent
Other assets
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Income Tax Disclosure [Text Block]
Income Taxes
Redeemable convertible preferred stock
Redeemable convertible preferred stock [Policy Text Block]
Redeemable convertible preferred stock.
Conversion of temporary to permanent equity, shares
Conversion of temporary to permanent equity, shares.
Conversion of redeemable convertible preferred stock to common stock upon initial public offering, Shares
Earnings Per Share [Text Block]
Net Loss Per Share
Number of Reportable Segments
Number of reportable segments
Stockholders' Equity Note [Abstract]
Harold Bernstein MD PhD [Member]
Harold Bernstein, M.D., Ph.D.
Harold Bernstein, M.D., Ph.D
Basis of presentation
Basis of Accounting, Policy [Policy Text Block]
Change in Fair Value of Derivative
Change in fair value of derivative.
Change in fair value of the derivative
MAZE Success Fee Derivative [Member]
MAZE success fee derivative.
MAZE Success Fee Derivative
Shares Reserved Under Twenty Nineteen And Twenty Twenty Five Equity Incentive Plan [Member]
Shares reserved under twenty nineteen and twenty twenty five equity incentive plan.
Shares Reserved Under 2019 and 2025 Equity Incentive Plan
Long-Term Debt
Total term loan
Credit Facility [Axis]
Tranche 1A [Member]
Tranche 1A [Member]
Tranche 1A
Debt Covenants [Axis]
Debt Covenants.
Stock, Class of Stock [Table]
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]
Reconciliation to cash, cash equivalents, and restricted cash:
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Unrealized Gains
Contractual Obligation
Contractual Obligation, Total
Obligation to pay
Revolving Credit Facility [Member]
Revolving Credit Facility
Proceeds from Stock Options Exercised
Proceeds from exercise of stock option awards
Final tranche
Final Tranche
Final tranche.
Geographical [Domain]
Schedule of Maturities of Long-Term Debt [Table Text Block]
Summary of Future Principal Loan Payments on Currently Outstanding Tranche 1A Loan
Statistical Measurement [Axis]
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Comprehensive loss:
Money Market Funds [Member]
Money Market Funds
Entity Interactive Data Current
Above Prime Rate [Member]
Above Prime Rate [Member]
Above Prime Rate.
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Common Stock, Value, Issued
Common stock, $0.001 par value; 500,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 55,504,574 and 49,335,551 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; 10,372 shares subject to repurchase as of June 30, 2026 and December 31, 2025
End of term charge
Long Term Debt End of Term Charge
Long term debt end of term charge.
Add: end of term charge
Summary of Computation of Basic and Diluted Net Loss Per Share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
US Government Agencies Debt Securities [Member]
U.S. Government Agency Securities
Debt Instrument, Interest Rate, Increase (Decrease)
Term loan facility, interest rate increase
Cash Equivalents and Marketable Securities
Cash, Cash Equivalent, and Marketable Security [Text Block]
Marketable securities
Liabilities
Total liabilities
Internal Research And Development Expenses
Internalresearchanddevelopmentexpenses.
Internal research and development expenses:
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total
Unamortized discount and issuance costs
Less: unamortized discount and issuance costs
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Financial Assets Measured at Fair Value on Recurring Basis
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Convertible Preferred Stock [Member]
Convertible Preferred Stock
Fair Value, Inputs, Level 3 [Member]
Level 3
Cash and Cash Equivalents, Fair Value Disclosure
Cash equivalents
Accounts payable
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accounts Payable, Total
Segment operating expenses
Operating Expenses
Total operating expenses
Shionogi Milestone Payment [Member]
Shionogi milestone payment.
Shionogi Milestone Payment
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Organization and Principal Activities
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Unvested Exercised Options Subject to Repurchase [Member]
Unvested exercised options subject to repurchase.
Unvested Exercised Options Subject to Repurchase
Maximum Benefically Owned Threshold Percentage Limit 1
Maximum benefically owned threshold percentage limit 1.
Maximum benefically owned threshold percentage limit 1
Price per share
Shares Issued, Price Per Share
Underwrittenregisteredoffering.
Underwritten Registered Offering
URO
Underwritten Registered Offering [Member]
Market Capitalization Greater Than or Equal to $450.0 Million and Principal of Less Than or Equal to $85.0 Million Outstanding
Market Capitalization Greater Than or Equal to $450.0 Million and Principal of Less Than or Equal to $85.0 Million Outstanding [Member]
Market capitalization greater than or equal to $450.0 million and principal of less than or equal to $85.0 million outstanding.
Shares sold
Common stock shares issued and sold
Issuance of common stock and pre-funded warrants, net of issuance costs, Shares
Issuance of common stock in connection with initial public offering/Issuance of common stock and pre-funded warrants to purchase common stock in connection with underwritten registered offering, net of issuance costs, Shares
Marketable Security, Unrealized Gain (Loss)
Net unrealized gain on marketable securities
Net unrealized loss on marketable securities
Aggregate Milestone Payments Upon The Sales Milestones
Milestone payment paid upon sales milestones
Milestone payment to be paid upon achivement of sales milestones.
Milestone payment to be paid upon achivement of sales milestones
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
Payment received
Warrants outstanding
Class of Warrant or Right, Outstanding
Additional term loan providing up to an aggregate
Additional term loan providing up to an aggregate
Additional term loan providing up to an aggregate
IPO [Member]
Initial Public Offering
IPO
Restricted Cash, Total
Restricted Cash
Restricted cash
Temporary Equity, Carrying Amount, Attributable to Parent
Beginning balance
Ending balance
Redeemable convertible preferred stock, $0.001 par value; no shares authorized, issued and outstanding as of September 30, 2025; 298,205,027 shares authorized and 297,205,041 shares issued and outstanding as of December 31, 2024; aggregate liquidation preference of $502,390 as of and December 31, 2024
Related Party Transactions [Abstract]
Payment of clinical development milestone
Payment Of Clinical Development Milestone
Payment Of clinical development milestone.
Subsequent Events
Subsequent Events [Text Block]
Fair Value Hierarchy and NAV [Axis]
Assets
Assets, Fair Value Disclosure [Abstract]
Corporate Debt Securities [Member]
Corporate debt securities
Debt Instrument, Unamortized Discount, Current
Unamortized debt discount
Debt Securities, Available-for-Sale
Debt Securities, Available-for-Sale, Total
Marketable securities
Aggregate Estimated Fair Value
Payments of Stock Issuance Costs
Issuance costs
Payment of deferred offering costs
Payment of offering costs
Operating Lease, Liability, Current
Operating lease liabilities, current
Warrants exercised
Pre Funded Warrant Exercised
Pre-funded warrant exercised.
Marketable Securities Non-Current [Member]
Marketable securities non-current.
Long-term Marketable Securities
Liabilities and Equity
Total liabilities and stockholders' equity
Research and Development Expense
Total research and development expenses
Research and development
Document Fiscal Period Focus
Unvested Restricted Stock Subject to Repurchase
Unvested Restricted Stock Subject to Repurchase [Member]
Unvested restricted stock subject to repurchase.
Deferred offering costs recorded in accrued expenses
Deferred Offering Costs Recorded in Accrued Expenses
Deferred offering costs recorded in accrued expenses.
Twenty Twenty Five Equity Incentive Plan [Member]
2025 Equity Incentive Plan
2025 Equity Incentive Plan.
Sale of Stock [Axis]
Entity Current Reporting Status
Use of Estimates, Policy [Policy Text Block]
Use of estimates
final tranche [Member]
Final Tranche
Final Tranche [Member]
Success Fee
Success fee.
Success fee
Fair Value, Inputs, Level 1 [Member]
Level 1
Class of Stock [Domain]
Accounts Payable, Current
Accounts Payable, Current, Total
Accounts payable
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Summary of Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders
Financial Instrument [Axis]
Total assets measured at fair value
Assets, Fair Value Disclosure
Document Transition Report
Commitments and Contingencies Disclosure [Abstract]
Shionogi & Co., Ltd [Member]
Shionogi & Co., Ltd member.
Shionogi Co Ltd
Subsequent Event [Line Items]
Extinguishment of Debt [Axis]
Class of Warrant or Right [Axis]
Liabilities, Current [Abstract]
Current liabilities:
Share-Based Payment Arrangement [Abstract]
Line of Credit Facility, Commitment Fee Amount
Term Loan Facility
Cash And Cash Equivalents Percentage Of Outstanding Debt
Cash and cash equivalents percentage of outstanding debt.
Cash and cash equivalents of percentage of outstanding loan amount
Weighted-average effective interest rate
Debt, Weighted Average Interest Rate
Common Stock
Common Stock [Member]
Credit Facility [Domain]
Statistical Measurement [Domain]
Debt Securities, Available-for-Sale [Line Items]
Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation
Less: weighted-average shares of common stock subject to repurchase
Less: weighted-average shares of common stock subject to repurchase
Equity, Attributable to Parent [Abstract]
Stockholders' equity (deficit):
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted-average shares of common stock outstanding used in the calculation of net loss per share, basic
Weighted-average shares of common stock outstanding used to compute net loss per share basic:
Assets [Abstract]
Assets
License Agreements [Abstract]
License agreements.
Line of Credit Facility, Capacity Available for Specific Purpose Other than for Trade Purchases
Line of credit
Market Capitalization Greater Than or Equal to $750.0 Million
Market Capitalization Greater Than or Equal to $750.0 Million [Member]
Market Capitalization Greater Than or Equal to $750.0 Million.
Number of Additional Term Loan Tranches
Number of additional term loan tranches.
Number of additional term loan tranches
Operating Lease, Expense
Non-cash lease expense
Entity Central Index Key
Line of Credit Facility [Table]
Class of Stock [Line Items]
Current Fiscal Year End Date
Debt, Policy [Policy Text Block]
Debt issuance costs and debt discount
Internal research and development expenses facilities, lab supplies and other costs
Internal research and development expenses facilities, lab supplies and other costs.
Facilities, lab supplies and other
Class of Warrant or Right [Domain]
Document Quarterly Report
Debt Instrument, Maturity Date
Maturity date
Debt Securities, Available-for-Sale [Table]
Cash and Cash Equivalents [Axis]
Long-Term Debt, Maturity, Remainder of Fiscal Year
2026
Fair Value, Inputs, Level 2 [Member]
Level 2
Direct external research and development expenses for MZE829 program
Direct external research and development expenses for MZE829 program.
MZE829
Trace License Agreement [Member]
Trace license agreement.
Trace License Agreement
Consortium Agreement and certain related amended agreements with University of Helsinki and other parties [Member]
Consortium agreement and certain related amended agreements with University of Helsinki and other parties.
Consortium Agreement and Certain Related Amended Agreements with University of Helsinki and Other Parties
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Cash provided by operations
Net cash used in operating activities
Entity Incorporation, State or Country Code
Net loss per share, diluted
Earnings Per Share, Diluted
Earnings Per Share, Diluted, Total
Net loss per share, diluted:
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period
Shares issued
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par or stated value per share
Preferred stock, par value
Net loss
Net loss
Early Repayment Of Debt Fee Percentage
Early repayment of debt fee percentage.
Exit fee, percentage
Pre Funded Warrants Exercised
Pre Funded warrants exercised.
Warrants exercised
Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Other Operating Assets, Total
Other assets
Other assets
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Cash, cash equivalents and marketable securities
Cash, Cash Equivalents, and Short-Term Investments
Cash, Cash Equivalents, and Short-Term Investments, Total
Interim Period, Costs Not Allocable [Domain]
Supplemental Balance Sheet Disclosures [Text Block]
Balance Sheet Components
Convertible promissory notes [Policy Text Block]
Convertible promissory notes.
Convertible promissory notes
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Preferred Stock, Liquidation Preference, Value
Preferred stock, liquidation preference, value
Measurement Frequency [Domain]
Series D 1 Redeemable Convertible Preferred Stock [Member]
Series D-1 Redeemable Convertible Preferred Stock
Series D-1 Redeemable Convertible Preferred Stock.
Equity Components [Axis]
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Investing activities
Pre Funded Warrants [Member]
Pre funded warrants.
Pre-Funded Warrants
Pre-Funded Warrants, Issued and Outstanding
Statement of Cash Flows [Abstract]
Fair Value Hierarchy and NAV [Domain]
Income Tax Disclosure [Abstract]
Reverse stock split of issued and outstanding shares of common stock
Stockholders' Equity, Reverse Stock Split
Purchase price per share or per unit of warrants or rights issued.
Class Of Warrant Or Right, Price Of Warrants Issued
Purchase price of warrants
Deferred offering costs
Deducted issuance costs
Underwriting discounts, commissions and other offering expenses
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other current assets
Prepaid expenses and other current assets
Sale of common stock maximum aggregate offering price
Sale of common stock maximum aggregate offering price
Sale of common stock maximum aggregate offering price
Fair Value Measurements
Fair Value Disclosures [Text Block]
Unrestricted Cash and Cash Equivalents Amounts to be Maintained at Fourty Percent of Outstanding Debt
Unrestricted Cash and Cash Equivalents Amounts to be Maintained at Fourty Percent of Outstanding Debt [Member]
Unrestricted cash and cash equivalents amounts to be maintained at fourty percent of outstanding debt member.
Debt Prepaid More Than 24 Months Less Than 36 Months After Closing Date [Member]
Debt prepaid more than 24 months less than 36 months after closing date.
Debt Prepaid More Than 24 Months Less Than 36 Months after Closing Date
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Preferred stock authorized
Class of Stock [Axis]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Total
Counterparty Name [Axis]
Shares Subject To Outstanding Restricted Stock Units [Member]
Shares subject to outstanding restricted stock units.
Shares Subject to Outstanding Restricted Stock Units
Number of Operating Segments
Number of operating segments
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income
Warrants Issued Price Per Share
Warrants issued price per share.
Warrants issued price per share
Unrestricted Cash and Cash Equivalents Amounts to be Maintained at Thirty-Five Percent of Outstanding Debt [Member]
Unrestricted cash and cash equivalents amounts to be maintained at thirty-five percent of outstanding debt.
Unrestricted Cash and Cash Equivalents Amounts to be Maintained at Thirty-Five Percent of Outstanding Debt
Draw Down Fee Due At Closing Date Percentage
Draw down fee due at closing date percentage.
Draw down fee due at closing date percentage
Temporary Equity, Shares Outstanding
Beginning balance, Shares
Ending balance, shares
Fair Value of Success Fee Derivative
Fair value of success fee derivative.
Fair value of success fee derivative
Net proceeds from shares issued and sold
Proceeds from initial public offering, net of offering costs paid
Proceeds from initial public offering, net
Debt Covenants.
Debt Covenants [Domain]
Segment Reporting, Policy [Policy Text Block]
Segment reporting
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Accrued expenses and other liabilities
Vesting of restricted stock and early exercised stock options
Adjustments To Additional Paid In Capital Vesting of Restricted Stock And Early Exercised Stock Options
Adjustments to additional paid in capital vesting of restricted stock and early exercised stock options.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Direct External Research And Development Expenses By Program
Directexternalresearchanddevelopmentexpensesbyprogram.
Direct external research and development expenses by program:
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance
Common stock, shares, outstanding
Stock options, aggregated shares, outstanding
Long-Term Debt, Maturity, Year Five
2031
Long-Term Debt, Current Maturities
Long-Term Debt, Current Maturities, Total
Less: current portion of term loan
Less: current portion of term loan
Unrealized Losses
Unrealized Losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Dividends, Common Stock, Total
Dividends, Common Stock
Common stock dividends declared
Document Type
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Operating activities
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Liabilities and Equity [Abstract]
Liabilities and Stockholders' Equity
Subsequent Event [Member]
Subsequent Event
Loss from operations
Operating Income (Loss)
Loss from operations
Segment loss from operations
Draw Down Fee Paid
Draw down fee paid.
Draw down fee paid
Marketable Securities
Marketable Securities, Policy [Policy Text Block]
Two Thousand And Twenty Six Pre Funded Warrants [Member]
Two thousand and twenty six pre funded warrants member.
Two Thousand and Twenty Six Pre Funded Warrants
2026 Pre-Funded Warrants
Proceeds from issuance of common stock under the two thousand twenty five employee stock purchase plan
Proceeds from issuance of common stock under the two thousand twenty five employee stock purchase plan.
Proceeds from issuance of common stock under the 2025 Employee Stock Purchase Plan
Entity File Number
Cash Cash Equivalents Marketable Securities Current And Non Current
Cash, cash equivalents, marketable securities current and non-current.
Cash, cash equivalents and marketable securities
Accrued Liabilities and Other Liabilities
Accrued expenses and other current liabilities
Total accrued expenses and other current liabilities
Location, Statement of Income, Balance [Axis]
Accumulated Deficit
Retained Earnings [Member]
Entity Registrant Name
Amy Bachrodt [Member]
Amy Bachrodt.
Amy Bachrodt
Accounting Policies [Abstract]
Depreciation, Total
Depreciation expense
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Net income
Net loss
Proceeds from Issuance of Debt
Proceeds from debt issuance, net
Debt Instrument, Interest Rate, Stated Percentage2
Debt instrument, interest rate, stated percentage2.
Term loan facility, interest rate percentage
Entity Address, Address Line One
UNITED STATES
United States
Redeemable Convertible Preferred Stock [Member]
Redeemable Convertible Preferred Stock
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Exercise of stock options, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance
Restricted stock units outstanding
Proceeds from Issuance or Sale of Equity
Proceeds from Issuance or Sale of Equity, Total
Proceeds from private placement
Net proceeds from issuance of common stock and pre-funded warrants in private placement
Net proceeds from issuance of common stock and pre-funded warrants
Aggregate principal amount of convertible promissory notes
Debt Instrument, Issued, Principal
Principal amount outstanding
Assets, Current
Total current assets
Common Stock, Voting Rights
Common stock, voting rights
Fair Value, Recurring and Nonrecurring [Table]
Earnings Per Share, Policy [Policy Text Block]
Net loss per share
Percentage of Voting Securities Held
Percentage of voting securities held.
Percentage of voting securities held
Series D Redeemable Convertible Preferred Stock [Member]
Series D Redeemable Convertible Preferred Stock
Series D Redeemable Convertible Preferred Stock.
Loss Contingencies [Line Items]
Nature of Expense [Axis]
Supplemental disclosure of cash flow information:
Supplemental Cash Flow Information [Abstract]
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
Entity Small Business
Term loan, non-current
Long-Term Debt, Excluding Current Maturities
Total term loan, net of current portion
Total term loan, net of current portion
Twenty Twenty Five Employee Stock Purchase Plan [Member]
2025 Employee Stock Purchase Plan
2025 Employee Stock Purchase Plan.
Accounting Policies [Line Items]
Accounting policies line Items.
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Total unrecognized compensation cost
Issuance Costs and Debt Discount Arising from Success Fee
Issuance costs and debt discount arising from success fee.
Issuance costs and debt discount arising from success fee
Long-Term Debt, Type [Axis]
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Common stock subject to repurchase
Common stock subject to repurchase.
Common stock, shares, subject to repurchase
Accounts receivable
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts Receivable, after Allowance for Credit Loss, Current, Total
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Organization consolidation and presentation of financial statement.
Employee-related Liabilities, Current
Employee-related Liabilities, Current, Total
Accrued compensation expenses
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Earnings Per Share [Abstract]
Net income (loss) per share attributable to common stockholders (see Note 11):
Summary of Components of Stock-based Compensation Expense
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]
Hercules Term Loan Facility [Member]
Hercules Term Loan Facility.
Hercules Term Loan Facility
Convertible Promissory Notes
Convertible Promissory Notes [Member]
Convertible Promissory Notes.
Proceeds from exercise of pre-funded warrants
Proceeds from Warrant Exercises
Leerink Partners LLC
Leerink Partners LLC [Member]
Leerink Partners LLC .
Two Thousand Twenty Six Sale Agreement [Member]
2026 sale agreement.
2026 Sale Agreement
Plan Name [Axis]
Subsequent Event Type [Axis]
Equity [Text Block]
Capital Structure
Measurement Frequency [Axis]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Financing activities
Direct external research and development expenses for MZE782 program
Direct external research and development expenses for MZE782 program.
MZE782
Loss in change in fair value of Convertible promissory notes
Loss in change in fair value of Convertible promissory notes.
Two Thousand and Twenty Five Pre Funded Warrants [Member]
2025 Pre-Funded Warrants.
2025 Pre-Funded Warrants
Entity Incorporation, Date of Incorporation
Date of incorporation
Marketable Securities, Noncurrent
Marketable securities, non-current
Entity Tax Identification Number
Conversion of preferred stock into common stock
Stock Issued During Period, Shares, Conversion of Convertible Securities
Conversion of redeemable convertible preferred stock to common stock upon initial public offering, Shares
Development And Regulatory Milestone [Member]
Development and regulatory milestone.
Development And Regulatory Milestone
Accounts receivable
Increase (Decrease) in Receivables
Increase (Decrease) in Receivables, Total
Accounts receivable
Shares Subject to Outstanding Stock Options [Member]
Shares subject to outstanding stock options.
Shares Subject to Outstanding Stock Options
Series C Redeemable Convertible Preferred Stock [Member]
Series C Redeemable Convertible Preferred Stock
Series C Redeemable Convertible Preferred Stock.
Equity Component [Domain]
Debt Prepaid On Or Within 12 Months Of Closing Date [Member]
Debt Prepaid on or Within 12 Months of Closing Date .
Debt Prepaid on or Within 12 Months of Closing Date
Entity Address, City or Town
Capital Expenditures Incurred but Not yet Paid
Purchases of property and equipment recorded in accounts payable and accrued expenses
2027
Long-Term Debt, Maturity, Year One
Income Tax Paid, after Refund Received
Income Taxes Paid, Net, Total
Income taxes paid
Stock Issued During Period, Value, New Issues
Issuance of common stock in connection with initial public offering/Issuance of common stock and pre-funded warrants to purchase common stock in connection with underwritten registered offereing, net of issuance costs
Restricted Cash, Noncurrent
Restricted cash
Entity Common Stock, Shares Outstanding
Schedule of Debt [Table Text Block]
Summary of Tranche 1A Loan
Net Income (Loss) Attributable to Parent [Abstract]
Numerator:
Commercial Paper [Member]
Commercial Paper
Underwriting Agreement
Underwriting Agreement [Member]
Underwritinga agreement.
Percentage of Warrants Maximum Benefically Owned Threshold Percentage Increase or Decrease
Percentage of warrants maximum benefically owned threshold percentage Increase or Decrease.
Percentage of warrants maximum benefically owned threshold percentage increase or decrease
Increase (Decrease) in Other Noncurrent Liabilities
Long-term liabilities
Long-term liabilities
Denominator:
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Antidilutive Security, Excluded EPS Calculation [Table]
Purchases of marketable securities
Payments to Acquire Marketable Securities
Statement [Table]
Share-Based Payment Arrangement, Expense
Stock-based compensation expense
Facility Charge Due At Closing Date Percentage
Facility charge due at closing date percentage.
Facility charge due at closing date percentage
Entity Shell Company
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash used in investing activities
Other income (expense):
Other Income and Expenses [Abstract]
Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]
Statement [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Liabilities
Contingent liabilities.
Contingent liabilities
AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax
Accumulated other comprehensive (loss) income
Maximum [Member]
Maximum
Stock Issuance Costs
Stock issuance costs.
Issuance costs
Debt Disclosure [Abstract]
Sale of Stock [Domain]
Facility charge for each subsequent term loan percentage
Facility Charge For Each Subsequent Term Loan Percentage
Facility charge for each subsequent term loan percentage.
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Net increase (decrease) in cash, cash equivalents, and restricted cash
Net increase in cash, cash equivalents and restricted cash
Subsequent Events [Abstract]
Investments, Debt and Equity Securities [Abstract]
Extinguishment of Debt, Type [Domain]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted average grant date fair value
Assets, Current [Abstract]
Current assets:
Liabilities, Fair Value Disclosure
Total liabilities measured at fair value
Jefferies LLC [Member]
Jefferies LLC [Member]
Accrued Professional Fees, Current
Accrued professional expenses
Marketable Securities [Line Items]
Document Fiscal Year Focus
Disclosure Loan And Security Agreements [Abstract]
Disclosure Loan And Security Agreements.
Accretion (Amortization) of Discounts and Premiums, Investments
Amortization of premiums on marketable securities, net
Amortization of premiums on marketable securities, net
Common Stock, Shares, Outstanding
Common stock, shares, outstanding
Beginning balance, Shares
Ending balance, Shares
Equity, Including Portion Attributable to Noncontrolling Interest
Equity, Including Portion Attributable to Noncontrolling Interest, Total
Beginning balance
Ending balance
Sales Milestone [Member]
Sales milestone.
Sales Milestone
Common Stock Voting Rights Number Of Votes
Common stock voting rights number of votes.
Number of vote
Financial Instruments [Domain]
Revenue recognition
Revenue from Contract with Customer [Policy Text Block]
Entity Ex Transition Period
Operating Lease, Liability, Noncurrent
Operating lease liabilities, net of current portion
Debt Securities, Available-for-Sale, Allowance for Credit Loss
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total
Allowance for credit losses
License Agreements [Table]
License agreements.
Other Accrued Liabilities, Current
Other
Security Exchange Name
Marketable Securities Remaining Contractual Maturity
Marketable securities remaining contractual maturity.
Marketable securities remaining contractual maturity
Accrued Research And Development Expenses Current
Accrued research and development expenses current.
Accrued research and development expenses
Market Capitalization Greater Than or Equal to $450.0 Million [Member]
Market Capitalization Greater Than or Equal to $450.0 Million.
Market Capitalization Greater Than or Equal to $450.0 Million
Convertible debt outstanding
Convertible Debt
Convertible Debt, Total
Series D Redeemable Convertible Preferred Stock
Series D Preferred Stock [Member]
New Accounting Pronouncements, Policy [Policy Text Block]
Recently adopted accounting pronouncements / New accounting pronouncements-Not yet adopted
Class of Warrant or Right, Exercise Price of Warrants or Rights
Exercise price of warrants
Entity Address, State or Province
Organization consolidation and presentation of financial statements.
Organization Consolidation and Presentation of Financial Statements [Table]
Debt Default Additional Interest Rate
Debt default additional interest rate.
Debt default interest rate
Shionogi License Agreement [Member]
Shionogi license agreement.
Shionogi License Agreement
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Unrecognized compensation cost expected to be recognized over a weighted-average period
Operating Lease, Right-of-Use Asset
Operating lease right-of-use asset
Amendment Flag
Loss Contingencies [Table]
Share-Based Payment Arrangement [Text Block]
Equity Incentive Plan and Stock-Based Compensation Expense
Debt Repaid More Than 24 Months Less Than 48 Months After Closing Date [Member]
Debt repaid more than 24 months less than 48 months after closing date.
Debt Repaid More Than 24 Months Less Than 48 Months After Closing Date
Interest expense on debt
Interest Expense, Debt
Interest Expense, Debt, Total
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Debt Instrument [Axis]
Total other income, net
Other Nonoperating Income (Expense)
Segment other income, net
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Total cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at end of the period
Cash, cash equivalents, and restricted cash at beginning of the period
Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]
Schedule of Common Stock Reserved for Future Issuance
Schedule of common stock reserved for future issuance.
License Agreements
License Agreements [TextBlock]
License agreements.
City Area Code
Stock Issued During Period, Value, Employee Stock Purchase Plan
Issuance of common stock under the 2025 Employee Stock Purchase Plan
Interest expense
Interest Expense, Nonoperating
Interest Expense, Nonoperating, Total
Interest expense
Preferred Stock
Preferred Stock [Member]
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item
Other items, net
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, cash equivalents and restricted cash
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions
Number of marketable securities that were in an unrealized loss position
Operating Expenses [Abstract]
Operating expenses:
2019 Equity Incentive Plan and 2025 Equity Incentive Plan
Twenty Nineteen Equity Incentive Plan and Twenty Twenty Five Equity Incentive Plan [Member]
Twenty nineteen equity incentive plan and twenty twenty five equity incentive plan.
Debt Instrument Prepayment Premium Percentage
Debt instrument prepayment premium percentage.
Term loan prepayment premium percentage
Common stock, par or stated value per share
Common stock, par value
Share price
Non Refundable Upfront Payment
Non refundable upfront payment.
Non refundable upfront payment
Atul Dandekar [Member]
Atul Dandekar.
Atul Dandekar
Liabilities, Current
Total current liabilities
US Government Corporations and Agencies Securities [Member]
U.S. Government Agency Securities
Milestone Payment
Milestone Payment
Milestone payment
Debt Securities, Available-for-Sale [Table Text Block]
Summary of Amortized Cost, Gross Unrealized Holding Gains and Losses, and Fair Value of the Company's Cash Equivalents Marketable Securities by Major Security Type
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Long-Term Debt, Maturity, Year Four
2030
Trading Symbol
Issuance costs
Placement fees, underwriting discounts, commissions and other offering expenses
Deduction of underwriting in discounts and commissions
Deduction of underwriting in discounts and commissions
Geographical [Axis]
Amortization of Debt Issuance Costs and Discounts
Amortization of Debt Issuance Costs and Discounts, Total
Amortization of debt discount and debt issuance costs
Fair Value Measurement, Policy [Policy Text Block]
Fair value measurement
Debt Issuance Costs Recorded in Accounts Payable and Accrued Expenses
Debt Issuance Costs Recorded in Accounts Payable and Accrued Expenses
Debt issuance costs recorded in accounts payable and accrued expenses
Subsequent Event [Table]
Entity Emerging Growth Company
License Agreements [Line Items]
License agreements.
Additional Paid-in Capital [Member]
Additional Paid-in Capital
Balance Sheet Components [Abstract]
Balance sheet components abstract.
Internal research and development expenses personnel-related costs
Internal research and development expenses personnel-related costs.
Personnel-related
Long-Term Debt, Gross
Term loan principal amount
Total future principal payments
Total future principal payments
Plan Name [Domain]
Unrestricted Cash and Cash Equivalents Amounts To Be Maintained at Fifty Percent of Outstanding Debt [Member]
Unrestricted Cash and cash equivalents amounts to be maintained at fifty percent of outstanding debt.
Unrestricted Cash and Cash Equivalents Amounts To Be Maintained at Fifty Percent of Outstanding Debt
Payment of offering costs for private placement
Payment of Offering Costs for Private Placement
Payment of offering costs for private placement.
Other Liabilities, Noncurrent
Other liabilities, non-current
Loan And Security Agreements [TextBlock]
Loan and security agreement.
Loan and security agreements
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Issuance of common stock under the 2025 Employee Stock Purchase Plan, Shares
U.S. Treasury Securities
US Treasury Securities [Member]
Placement fees and other offering expenses
Offering and Organizational Costs, Expense
Offering and Organizational Costs, Expense, Total
Additional Tranches [Member]
Additional tranches.
Additional Tranches
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Supplemental disclosure of non-cash investing and financing activities
Cover [Abstract]
Debt Repayment After 48 Months of Closing Date [Member]
Debt repayment after 48 months of closing date.
Debt Repayment After 48 Months of Closing Date
Shares reserved under twenty twenty five employee stock purchase plan [Member]
Shares Reserved Under 2025 Employee Stock Purchase Plan
Shares Reserved Under 2025 Employee Stock Purchase Plan.
Accounting Policies [Table]
Accounting policies table.
Marketable Securities [Table]
Weighted-average shares of common stock to be issued upon exercise of pre-funded warrants
Weighted-average shares of common stock to be issued upon exercise of pre-funded warrants.
Add: weighted-average shares of common stock to be issued upon exercise of pre-funded warrants
Long-Term Debt, Type [Domain]
Jason Coloma [Member]
Jason Coloma.
Jason Coloma
Share-Based Payment Arrangement, Noncash Expense
Share-Based Payment Arrangement, Noncash Expense, Total
Stock-based compensation expense
Additional Paid in Capital
Additional Paid in Capital, Total
Additional paid-in-capital
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Debt Prepaid More Than 12 Months Less Than 24 Months After Closing Date [Member]
Debt prepaid more than 12 months less than 24 months after closing date.
Debt Prepaid More Than 12 Months Less Than 24 Months After Closing Date
Fair Value Disclosures [Abstract]
Cash and Cash Equivalent
Cash and Cash Equivalents, at Carrying Value, Total
Cash and cash equivalents
Payments of Debt Issuance Costs
Payment of debt issuance costs
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by financing activities
Debt Repayment After 36 Months of Closing Date [Member]
Debt Repayment After 36 Months of Closing Date.
Debt Repayment After 36 Months of Closing Date
Achievement Of Clinical Development Milestone
Achievement of Clinical Development Milestone.
Achievement of clinical development milestone
Credit Line Success Fee Derivative Fair Value Disclosure
Credit line success fee derivative
Credit line success fee derivative fair value disclosure.
Direct external research and development expenses for discovery research and other programs
Direct external research and development expenses for discovery research and other programs.
Discovery research and other programs
Entity Filer Category
Debt Instrument, Name [Domain]
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Draw Down Fee Of Each Subsequent Term Loan Percentage
Draw down fee of each subsequent term loan percentage.
Draw down fee for each subsequent term loan percentage
Marketable Securities, Current
Marketable securities, current
Series A Redeemable Convertible Preferred Stock [Member]
Series A Redeemable Convertible Preferred Stock
Series A Redeemable Convertible Preferred Stock.
Conversion of Temporary to Permanent Equity Value
Conversion of temporary to permanent equity value.
Conversion of redeemable convertible preferred stock to common stock upon initial public offering
Conversion of redeemable convertible preferred stock to common stock upon initial public offering
Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
Property, Plant and Equipment, Net, Total
Property and equipment, net
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer
Number of marketable securities unrealized loss positions for 12 months or longer
Revenue
Revenue from Contract with Customer, Excluding Assessed Tax, Total
License revenue
Revenue
Entity Address, Postal Zip Code
Statement of Financial Position [Abstract]
Deferred Offering Costs [Policy Text Block]
Policy on deferred costs directly attributable to a proposed or actual offering of securities.
Deferred offering costs
Local Phone Number